COMPOSITION VACCINALE POUR LA PRÉVENTION OU LE TRAITEMENT D'UNE MALADIE ŒDÉMATEUSE PORCINE, COMPRENANT UNE PROTÉINE RECOMBINANTE FRAGMENT TERMINAL STX2EA-C-PENTAMÈRE STX2EB EN TANT QU'ANTIGÈNE
전북대학교산학협력단;주식회사 코미팜;INDUSTRIAL COOPERATION FOUNDATION CHONBUK NATIONAL UNIVERSITY;KOMIPHARM INTERNATIONAL CO., LTD
发明人:
HUR, Jin,허진,MOON, Seong Cheol,문성철,JUNG, Ho Kyoung,정호경,PARK, Su Yeon,박수연,PARK, Jung Hee,박정희,KIM, Won Il,김원일,KIM, So Young,김소영,SEO, Byoung Ju,서병주,JEONG, Chang Gi,정창기,MOON, Ja Young,문자영,KIM, Won Kyoung,김
申请号：
KRKR2019/016771
公开号：
WO2020/111885A1
申请日:
2019.11.29
申请国别(地区):
KR
年份:
2020
代理人:
摘要：
In the present invention, in order to overexpress a Stx2eA-C-terminal fragment-Stx2eB-pentameric recombinant protein, a Stx2eA-C-terminal fragment gene and a Stx2eB gene, among Stx2e toxins which are one of the causes of porcine edema disease, were cloned into pTWIN1 and pET30a, respectively, and then the vectors were transformed into E.coli BL21(DE3)pLysS. When five Stx2eB monomers expressed from a Stx2eB gene are gathered, monomers form a pentagon structure so as to form a Stx2eB pentamer, and the Stx2eB pentamer and a Stx2eA-C-terminal fragment are coupled so that a stable Stx2eA-C-terminal fragment-Stx2eB-pentameric recombinant protein is produced. A recombinant protein thus produced and an Alum adjuvant were mixed and inoculated, as an antigen of a vaccine for preventing edema disease, in various concentrations into the muscles when piglets were 5 days old and 4 weeks old. After inoculation, in the piglets from groups inoculated with 50 ug and 100 ug of the Stx2eA-C-terminal fragment-Stx2eB-pentameric recombinant protein, an antibody titer that is more remarkable than that of a control group was observed. Although mortality due to clinical symptoms, occurring at a rate similar to that of the control group, was observed in the piglets of a group inoculated with 25 ug, in a group inoculated with 50 ug, a mortality rate decrease by approximately 42% in comparison to the control group was observed. In addition, in a group inoculated with 100 ug, no clinical symptoms and mortality of edema disease were observed. Moreover, in a group inoculated with Stx2eB only and an alum adjuvant, 80% of the inoculated group died. Therefore, a recombinant Stx2eA-C-terminal fragment and a Stx2eB protein of the present invention are one type of toxoid vaccines, are toxoids on which a site where toxins adhere to cells is maintained and which have no toxic ingredient, and allows anti-Stx2eB antibody to prevent the adhesion of Stx2e toxins to effective cells, thereby being expected to b
